VJOncology is committed to improving our service to you

ESMO 2018 | Liquid biopsy to inform treatment and monitoring of NSCLC

VJOncology is committed to improving our service to you

Benjamin Besse

Benjamin Besse, MD, PhD, of the Gustave Roussy Institute, Villejuif, France, discusses the value of liquid biopsy in detecting RET fusions/mutations in patients with non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC), at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Liquid biopsy may not only inform the use of RET-inhibitor treatments like LOXO-292, but also aid monitoring of drug efficacy and even emergence of treatment resistance.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter